Echocardiographic Assessment and CLInical imPlication of Functional tricuSpid rEgurgitation in Heart Failure With Reduced or Preserved Ejection Fraction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-11-11

Study Completion Date

2024-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Purpose Functional tricuspid regurgitation (FTR) has been shown to be associated with increased morbidity and mortality in several clinical conditions, including heart failure (HF) with reduced left ventricular ejection fraction as well as pulmonary arterial hypertension (PAH). We have designed a study aiming at: characterizing the echocardiographic morphology of the tricuspid valve apparatus and the pathophysiology of FTR in heart failure with reduced, mid-range or preserved left ventricular ejection fraction (HFrEF, HFmrEF, HFpEF) and in PAH patients; correlating the morphologic characteristics of tricuspid valve apparatus with hemodynamic severity of FTR; correlating the severity of FTR with the clinical condition and outcome. Methods The study will be a non-interventional, prospective, international, multicenter, longitudinal study. The minimum number of patients which are expected to be enrolled is 300 HF patients, including HFrEF, HFmrEF and HFpEF patients, whereas 100 PAH patients will serve as control. The patients will be enrolled in 20 centers in Europe, North America and Saudi Arabia. The echocardiographic parameters will be analyzed by the local investigators; a quality control committee will evaluate all data entered in the database to identify potential outliers and a random sample of 10% of cases will be blindly re-analysed in a central core-lab. Conclusions This study has been designed to improve our understanding of pathophysiological mechanisms and clinical relevance of FTR across all HF phenotypes. The results could potentially allow a more appropriate selection of heart failure patients with FTR for tricuspid valve intervention by percutaneous or surgical repair or replacement.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prevalence and Prognostic Relevance of Tricuspid Regurgitation in Different Heart Failure Entities

NCT04570098

Tricuspid Regurgitation Heart Failure

COMPLETED

Cardiac Remodeling and Prognosis in Secondar Tricuspid Regurgitation

NCT03159923

Remodeling, Cardiac Tricuspid Regurgitation

COMPLETED

The FUnctional TricUspid REgurgitation by 3D EChocardiography Cooperative Study

NCT05747404

Heart Valve Incompetence Echocardiography, Transthoracic

RECRUITING

Prospective Study of Heart Failure With Preserved Left Ventricular Ejection Fraction

NCT01091467

Congestive Heart Failure Left Ventricular Ejection Fraction Heart Failure With Preserved Ejection Fraction

COMPLETED

Hemodynamic Implications of Transcatheter Tricuspid Valve Repair in HFpEF Patients

NCT04782908

Congestive Heart Failure Tricuspid Regurgitation

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Functional Tricuspid Regurgitation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pulmonary arterial hypertension

All patients with pulmonary arterial hypertension and significant functional tricuspid regurgitation